Patents by Inventor SABENA UDDOWLA BLAKENEY

SABENA UDDOWLA BLAKENEY has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • MONOCLONAL ANTIBODY AGAINST NOVEL EPITOPES OF FOOT-AND-MOUTH DISEASE VIRUS PROTEIN 3ABC AND USES THEREOF
    Publication number: 20180346553
    Abstract: This disclosure pertains to isolated antibodies or antigen binding fragments thereof that specifically bind to the 3ABC non-structural protein of Foot-and-Mouth Disease virus (FMDV), wherein the antibodies or antigen binding fragments thereof recognize the amino acid sequence of SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6 or SEQ ID NO: 12. Accordingly, this disclosure also pertains to polypeptides having an amino acid sequence selected from SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5 or SEQ ID NO: 12. Monoclonal antibody Mab 40C8 is also provided. The current disclosure also pertains to methods of detecting FMDV infection in an animal (including assays differentiating infected animals from vaccinated animals (DIVA)) and kits for performing the detection methods.
    Type: Application
    Filed: July 30, 2018
    Publication date: December 6, 2018
    Inventors: ALFONSO CLAVIJO, AIDA ELIZABETH RIEDER, ABU SAYED, MANGKEY A. BOUNPHENG, THOMAS G. BURRAGE, BROOKE A. DANCHO, SABENA UDDOWLA BLAKENEY
  • Monoclonal antibody against novel epitopes of foot-and-mouth disease virus protein 3ABC and uses thereof
    Patent number: 10035841
    Abstract: This disclosure pertains to isolated antibodies or antigen binding fragments thereof that specifically bind to the 3ABC non-structural protein of Foot-and-Mouth Disease virus (FMDV), wherein the antibodies or antigen binding fragments thereof recognize the amino acid sequence of SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6 or SEQ ID NO: 12. Accordingly, this disclosure also pertains to polypeptides having an amino acid sequence selected from SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5 or SEQ ID NO: 12. Monoclonal antibody Mab 40C8 is also provided. The current disclosure also pertains to methods of detecting FMDV infection in an animal (including assays differentiating infected animals from vaccinated animals (DIVA)) and kits for performing the detection methods.
    Type: Grant
    Filed: January 29, 2016
    Date of Patent: July 31, 2018
    Assignees: THE TEXAS A&M UNIVERSITY SYSTEM, THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY OF AGRICULTURE, THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY OF HOMELAND SECURITY
    Inventors: Alfonso Clavijo, Aida Elizabeth Rieder, Abu Sayed, Mangkey A. Bounpheng, Thomas G. Burrage, Brooke A. Dancho, Sabena Uddowla Blakeney
  • MONOCLONAL ANTIBODY AGAINST NOVEL EPITOPES OF FOOT-AND-MOUTH DISEASE VIRUS PROTEIN 3ABC AND USES THEREOF
    Publication number: 20170218053
    Abstract: This disclosure pertains to isolated antibodies or antigen binding fragments thereof that specifically bind to the 3ABC non-structural protein of Foot-and-Mouth Disease virus (FMDV), wherein the antibodies or antigen binding fragments thereof recognize the amino acid sequence of SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6 or SEQ ID NO: 12. Accordingly, this disclosure also pertains to polypeptides having an amino acid sequence selected from SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5 or SEQ ID NO: 12. Monoclonal antibody Mab 40C8 is also provided. The current disclosure also pertains to methods of detecting FMDV infection in an animal (including assays differentiating infected animals from vaccinated animals (DIVA)) and kits for performing the detection methods.
    Type: Application
    Filed: January 29, 2016
    Publication date: August 3, 2017
    Inventors: ALFONSO CLAVIJO, AIDA ELIZABETH RIEDER, ABU SAYED, MANGKEY A. BOUNPHENG, THOMAS G. BURRAGE, BROOKE A. DANCHO, SABENA UDDOWLA BLAKENEY